Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from CANbridge Pharmaceuticals Inc. ( (HK:1228) ).
CANbridge Pharmaceuticals Inc. announced the resignation of Dr. Fangxin Li as a non-executive director and member of the remuneration committee, effective June 25, 2025, due to changes in his work arrangements. This resignation has resulted in the remuneration committee falling below its required number of members, prompting the company to seek a suitable replacement. Additionally, the company has withdrawn an ordinary resolution related to Dr. Li’s proposed re-election at the upcoming annual general meeting, while all other meeting details remain unchanged.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases and targeted cancers. The company operates primarily in the healthcare industry, aiming to address unmet medical needs in its market focus areas.
Average Trading Volume: 5,188,094
Technical Sentiment Signal: Hold
Current Market Cap: HK$142.3M
For detailed information about 1228 stock, go to TipRanks’ Stock Analysis page.